AR087472A2 - Agentes anti-infecciosos y su uso - Google Patents
Agentes anti-infecciosos y su usoInfo
- Publication number
- AR087472A2 AR087472A2 ARP120102873A ARP120102873A AR087472A2 AR 087472 A2 AR087472 A2 AR 087472A2 AR P120102873 A ARP120102873 A AR P120102873A AR P120102873 A ARP120102873 A AR P120102873A AR 087472 A2 AR087472 A2 AR 087472A2
- Authority
- AR
- Argentina
- Prior art keywords
- group
- amino
- heterocyclyl
- independently selected
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Se relaciona con: (a) compuestos y sales de los mismos que, entre otros, inhiben el HCV; (b) intermediarios de utilidad para la preparación de dichos compuestos y sales; (c) composiciones que comprenden dichos compuestos y sales; (d) métodos para preparar dichos intermediarios, compuestos, sales y composiciones; (e) métodos de uso de dichos compuestos, sales y composiciones; y (f) conjuntos de elementos que comprenden dichos compuestos, sales y composiciones.Reivindicación 1: Un compuesto o sal del mismo, caracterizado porque: el compuesto corresponde en estructura a la fórmula (1); - - * - - se selecciona entre el grupo que consiste en enlace simple carbono- carbono y enlace doble carbono-carbono; R1 se selecciona entre el grupo que consiste en hidrógeno, metilo, y grupo protector de nitrógeno; R2 se selecciona entre el grupo que consiste en hidrógeno, halo, hidroxi, metilo, ciclopropilo, y ciclobutilo; R3 se selecciona entre el grupo que consiste en hidrógeno, halo, oxo, y metilo; R4 se selecciona entre el grupo que consiste en halo, alquilo, alquenilo, alquinilo, nitro, ciano, azido, alquiloxi, alqueniloxi, alquiniloxi, amino, aminocarbonilo, aminosulfonilo, alquilsulfonilo, carbociclilo, y heterociclilo, donde: (a) los grupos amino, aminocarbonilo, y aminosulfonilo están opcionalmente sustituidos con: (i) uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, y alquilsulfonilo, o (ii) dos sustituyentes que, junto con el nitrógeno de amino, forman un heterociclilo de anillo único, y (b) los grupos alquilo, alquenilo, alquinilo, alquiloxi, alqueniloxi, alquiniloxi, y alquilsulfonilo, están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en halo, oxo, nitro, ciano, azido, hidroxi, amino, alquiloxi, trimetilsililo, carbociclilo, y heterociclilo, donde: el grupo amino está opcionalmente sustituido con: (i) uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, alquilcarbonilo, alquilsulfonilo, alquiloxicarbonilo, carbociclilo, heterociclilo, carbociclilalquilo, y heterociclilalquilo, o (ii) dos sustituyentes que, junto con el nitrógeno de amino, forman un heterociclilo de anillo único, y (c) los grupos carbociclilo y heterociclilo están opcionalmente sustituidos con hasta tres sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halo, oxo, nitro, ciano, azido, hidroxi, amino, alquiloxi, trimetilsililo, carbociclilo, y heterociclilo, donde: el grupo amino está opcionalmente sustituido con: (i) uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, alquilcarbonilo, alquilsulfonilo, alquiloxicarbonilo, carbociclilo, heterociclilo, carbociclilalquilo, y heterociclilalquilo, o (ii) dos sustituyentes que, junto con el nitrógeno de amino, forman un heterociclilo de anillo único; R5 se selecciona entre el grupo que consiste en hidrógeno, hidroxi, alquilo, alquenilo, alquinilo, alquiloxi, alqueniloxi, alquiniloxi, alquilsulfoniloxi, carbociclilsulfoniloxi, haloalquilsulfoniloxi, y halo; R6 se selecciona entre el grupo que consiste en carbociclilo de 2 anillos fusionados y heterociclilo de 2 anillos fusionados, donde cada uno de dichos sustituyentes está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en RE, RF, RG, RH, RI, RJ, y RK; cada RE se selecciona en forma independiente entre el grupo que consiste en halo, nitro, hidroxi, oxo, carboxi, ciano, amino, imino, azido, y aldehído, donde: el grupo amino está opcionalmente sustituido con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, y alquinilo; cada RF se selecciona en forma independiente entre el grupo que consiste en alquilo, alquenilo, y alquinilo, donde: cada uno de dichos sustituyentes está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en carboxi, hidroxi, halo, amino, imino, nitro, azido, oxo, aminosulfonilo, alquilsulfonilo, alquiloxicarbonilo, alqueniloxicarbonilo, alquiniloxicarbonilo, alquilcarboniloxi, alquenilcarboniloxi, alquinilcarboniloxi, alquiloxi, alqueniloxi, alquiniloxi, carbociclilo, heterociclilo, ciano, y aminocarbonilo, donde: los grupos amino, imino, aminosulfonilo, aminocarbonilo, carbociclilo, y heterociclilo están opcionalmente sustituidos con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, alquilsulfonilo, alquenilsulfonilo, alquinilsulfonilo, alquilsulfonilamino, hidroxi, y alquiloxi, donde: la porción amino del alquilsulfonilamino está opcionalmente sustituida con un sustituyente seleccionado entre el grupo que consiste en alquilo, alquenilo, y alquinilo; cada RG se selecciona en forma independiente entre el grupo que consiste en carbociclilo y heterociclilo, donde: cada uno de dichos sustituyentes está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, carboxi, hidroxi, halo, amino, nitro, azido, oxo, aminosulfonilo, alquiloxicarbonilo, alqueniloxicarbonilo, alquiniloxicarbonilo, alquilcarboniloxi, alquenilcarboniloxi, alquinilcarboniloxi, alquiloxi, alqueniloxi, alquiniloxi, carbociclilo, heterociclilo, ciano, y aminocarbonilo, donde: los grupos amino, aminosulfonilo, y aminocarbonilo están opcionalmente sustituidos con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, alquilsulfonilo, alquenilsulfonilo, y alquinilsulfonilo; cada RH se selecciona en forma independiente entre el grupo que consiste en alquiloxi, alqueniloxi, alquiniloxi, alquilsulfoniloxi, alquenilsulfoniloxi, y alquinilsulfoniloxi, donde: cada uno de dichos sustituyentes está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en carboxi, hidroxi, halo, amino, nitro, azido, oxo, aminosulfonilo, alquiloxicarbonilo, alqueniloxicarbonilo, alquiniloxicarbonilo, alquilcarboniloxi, alquenilcarboniloxi, alquinilcarboniloxi, alquiloxi, alqueniloxi, alquiniloxi, carbociclilo, heterociclilo, ciano, y aminocarbonilo, donde: los grupos amino, aminosulfonilo, y aminocarbonilo están opcionalmente sustituidos con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, alquilsulfonilo, alquenilsulfonilo, y alquinilsulfonilo; cada RI se selecciona en forma independiente entre el grupo que consiste en alquilcarbonilo, alquenilcarbonilo, alquinilcarbonilo, aminocarbonilo, alquiloxicarbonilo, carbociclilcarbonilo, y heterociclilcarbonilo, donde: (a) los grupos alquilcarbonilo, alquenilcarbonilo, y alquinilcarbonilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en carboxi, hidroxi, halo, amino, nitro, azido, oxo, aminosulfonilo, alquiloxicarbonilo, alqueniloxicarbonilo, alquiniloxicarbonilo, alquilcarboniloxi, alquenilcarboniloxi, alquinilcarboniloxi, alquiloxi, alqueniloxi, alquiniloxi, carbociclilo, heterociclilo, ciano, y aminocarbonilo, y (b) el grupo aminocarbonilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, alquiloxialquilo, carbociclilo, heterociclilo, alquilsulfonilo, y alquilsulfonilamino, donde: los grupos carbociclilo y heterociclilo están opcionalmente sustituidos con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en halo, alquilo, y oxo; cada RJ se selecciona en forma independiente entre el grupo que consiste en carbociclilsulfonilamino, heterociclilsulfonilamino, alquilcarbonilamino, alquenilcarbonilamino, alquinilcarbonilamino, alquiloxicarbonilamino, alqueniloxicarbonilamino, alquinhloxicarbonilamino, alquilsulfonilamino, alquenilsulfonilamino, alquinilsulfonilamino, aminocarbonilamino, alquiloxicarbonilaminoimino, alquilsulfonilaminoimino, alquenilsulfonilaminoimino, y alquirtilsulfonilaminoimino, donde: (a) el grupo amino de dichos sustituyentes está opcionalmente sustituido con un sustituyente seleccionado en forma independiente entre el grupo que consiste en carbociclilalquilo, heterociclilalquilo, alquilcarboniloxi, aminocarbonilalquilo, alquilo, alquenilo, alquinilo, alquilcarbonilo, alquenilcarbonilo, alquinilcarbonilo, alquiloxicarbonilo, alquiloxialquiloxicarbonilo, alquilcarboniloxialquilo, y alquilsulfonilo, donde: (i) la porción carbociclilo del carbociclilalquilo y la porción heterociclilo del heterociclilalquilo están opcionalmente sustituidas con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, carboxi, hidroxi, alquiloxi, alqueniloxi, alquiniloxi, halo, nitro, ciano, azido, oxo, y amino, y (ii) la porción amino del aminocarbonilalquilo está opcionalmente sustituida con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, y alquinilo, (b) los grupos alquilo, alquenilo, y alquinilo de dichos sustituyentes están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en carboxi, halo, oxo, amino, alquiloxicarbonilo, alquilcarboniloxi, hidroxi, alquiloxi, carbociclilo, heterociclilo, y ciano, donde: el grupo amino está opcionalmente sustituido con uno o dos sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, alquiloxi, alqueniloxi, y alquiniloxi, donde: el grupo alquilo está
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97287707P | 2007-09-17 | 2007-09-17 | |
US9679108P | 2008-09-13 | 2008-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087472A2 true AR087472A2 (es) | 2014-03-26 |
Family
ID=39948002
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104045A AR070027A1 (es) | 2007-09-17 | 2008-09-17 | Agentes anti-infecciosos contra el virus hcv |
ARP120102873A AR087472A2 (es) | 2007-09-17 | 2012-08-06 | Agentes anti-infecciosos y su uso |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104045A AR070027A1 (es) | 2007-09-17 | 2008-09-17 | Agentes anti-infecciosos contra el virus hcv |
Country Status (31)
Country | Link |
---|---|
US (3) | US8415351B2 (es) |
EP (2) | EP2725015A1 (es) |
JP (2) | JP5734654B2 (es) |
KR (2) | KR101552474B1 (es) |
CN (2) | CN102746239B (es) |
AR (2) | AR070027A1 (es) |
AU (1) | AU2008302448B2 (es) |
BR (1) | BRPI0816994B8 (es) |
CA (2) | CA2699981C (es) |
CL (2) | CL2008002794A1 (es) |
CO (1) | CO6260076A2 (es) |
CR (2) | CR11316A (es) |
DO (2) | DOP2010000084A (es) |
ES (1) | ES2453591T3 (es) |
GT (1) | GT201000061A (es) |
HK (1) | HK1147256A1 (es) |
IL (1) | IL204547A (es) |
IN (1) | IN2012DN05113A (es) |
MX (2) | MX2010002905A (es) |
MY (1) | MY162760A (es) |
NZ (3) | NZ600371A (es) |
PA (1) | PA8796201A1 (es) |
PE (2) | PE20130209A1 (es) |
PH (1) | PH12013500365A1 (es) |
RU (2) | RU2543620C2 (es) |
SG (1) | SG183733A1 (es) |
TW (2) | TWI437994B (es) |
UA (1) | UA117800C2 (es) |
UY (1) | UY31344A1 (es) |
WO (1) | WO2009039127A1 (es) |
ZA (2) | ZA201204224B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009039127A1 (en) | 2007-09-17 | 2009-03-26 | Abbott Laboratories | Uracil or thymine derivative for treating hepatitis c |
EP2548873A1 (en) | 2007-09-17 | 2013-01-23 | Abbott Laboratories | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
PT2639226T (pt) | 2007-09-17 | 2016-12-09 | Abbvie Bahamas Ltd | Pirimidinas anti-infeciosas e suas utilizações |
CA2705586A1 (en) * | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-heterocyclic substituted indole derivatives and methods of use thereof |
JP2011528686A (ja) | 2008-07-23 | 2011-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
BRPI0920513A2 (pt) | 2008-09-26 | 2019-09-24 | F Hoffamann La Roche Ag | derivados de pirina ou pirazina para tratar hcv |
EP2411372B1 (en) * | 2009-03-24 | 2014-07-23 | AbbVie Bahamas Ltd. | Process for preparing an antiviral compound |
WO2010111437A1 (en) * | 2009-03-25 | 2010-09-30 | Abbott Laboratories | Antiviral compounds and uses thereof |
WO2010111653A2 (en) * | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
EP2421831A1 (en) | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
AR077004A1 (es) | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
EP2445875A2 (en) | 2009-06-24 | 2012-05-02 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compound |
JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
JP2013511489A (ja) * | 2009-11-21 | 2013-04-04 | エフ.ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
AR079440A1 (es) * | 2009-12-14 | 2012-01-25 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
JP5651239B2 (ja) | 2010-07-07 | 2015-01-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 複素環式抗ウイルス化合物 |
AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
MX338725B (es) | 2010-07-16 | 2016-04-28 | Abbvie Bahamas Ltd | Ligando de fosfina para reacciones cataliticas. |
US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
MY167881A (en) * | 2010-07-16 | 2018-09-26 | Abbvie Bahamas Ltd | Process for preparing antiviral compounds |
RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Npy y5受容体拮抗作用を有するヘテロ環誘導体 |
MX2013001273A (es) | 2010-08-13 | 2013-04-10 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
CA2829768A1 (en) | 2011-03-18 | 2012-09-27 | Abbvie Inc. | Formulations of phenyl uracil compounds |
CN103764169B (zh) * | 2011-03-31 | 2017-06-13 | 康斯坦策·沙费尔 | 用于非病毒转移核酸的全氟化化合物 |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | 1,3−ジヨードヒダントイン類の製造方法 |
KR20140062476A (ko) | 2011-08-01 | 2014-05-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 우라실 유도체 및 그 의약 용도 |
GB2515941A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
EA201490836A1 (ru) | 2011-10-21 | 2014-11-28 | Эббви Инк. | Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
AP3613A (en) | 2012-05-15 | 2016-02-29 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1 |
KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
PT2900637T (pt) | 2012-05-15 | 2017-11-15 | Novartis Ag | Derivados de amida de pirimidina, piridina e pirazina substituídos com tiazole ou imidazole e compostos relacionados como inibidores de abl1, abl2 e bcr-abl1 para tratamento do cancro, infecções virais específicas e disturbios do snc específicos |
MX2014013373A (es) | 2012-05-15 | 2015-08-14 | Novartis Ag | Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1. |
WO2014004674A2 (en) | 2012-06-27 | 2014-01-03 | Abbvie Inc. | Methods for treating hcv |
JP6469571B2 (ja) * | 2012-08-21 | 2019-02-13 | アッヴィ・アイルランド・アンリミテッド・カンパニー | 抗ウイルス性化合物を調製するための方法 |
SG11201503051QA (en) | 2012-10-18 | 2015-05-28 | Abbvie Inc | Formulations of pyrimidinedione derivative compounds |
JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ[1,2−d;4,5−d’]ビスチアゾール化合物の製造方法 |
CA2916912A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
ES2728531T3 (es) | 2013-07-08 | 2019-10-25 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con C-N como agentes para combatir parásitos |
ES2927955T3 (es) | 2013-09-11 | 2022-11-14 | Univ Emory | Composiciones de nucleótidos y nucleósidos y sus usos |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
US20150209403A1 (en) | 2014-01-28 | 2015-07-30 | Abbvie Inc. | Dose Adjustment |
SG11201606080SA (en) | 2014-02-03 | 2016-08-30 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
DK3174868T3 (da) | 2014-08-01 | 2021-11-08 | Nuevolution As | Forbindelser, der er aktive mod bromodomæner |
US20160074462A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Method of Treating HCV |
HUE042335T2 (hu) | 2014-10-14 | 2019-06-28 | Vitae Pharmaceuticals Inc | ROR-gamma dihidropirrolopiridin inhibitorai |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
CN108137514A (zh) * | 2015-07-30 | 2018-06-08 | 百时美施贵宝公司 | 芳基取代的二环杂芳基化合物 |
EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
EP3377482B1 (en) | 2015-11-20 | 2021-05-12 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
MX2020000887A (es) | 2017-07-24 | 2020-07-22 | Vitae Pharmaceuticals Llc | Inhibidores de ror?. |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
EP0442473B1 (en) | 1990-02-15 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
NL9001075A (es) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
JP3824935B2 (ja) * | 1999-12-06 | 2006-09-20 | エフ.ホフマン−ラ ロシュ アーゲー | 4−ピリミジニル−n−アシル−l−フェニルアラニン |
US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
IL167954A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | History of pyrimidine |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
TWI394747B (zh) * | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
EP2548873A1 (en) * | 2007-09-17 | 2013-01-23 | Abbott Laboratories | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
WO2009039127A1 (en) * | 2007-09-17 | 2009-03-26 | Abbott Laboratories | Uracil or thymine derivative for treating hepatitis c |
PT2639226T (pt) * | 2007-09-17 | 2016-12-09 | Abbvie Bahamas Ltd | Pirimidinas anti-infeciosas e suas utilizações |
JP2011528686A (ja) | 2008-07-23 | 2011-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
-
2008
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en active Application Filing
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Protection Beyond IP Right Term
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko active Protection Beyond IP Right Term
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2011
- 2011-02-11 HK HK11101327.9A patent/HK1147256A1/xx not_active IP Right Cessation
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087472A2 (es) | Agentes anti-infecciosos y su uso | |
AR116978A1 (es) | Fungicidas de tolilo sustituido | |
RU2011142979A (ru) | Противовирусные соединения и их применения | |
JP2010539186A5 (es) | ||
AR122776A2 (es) | Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus métodos y usos | |
AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
AR081998A1 (es) | Compuestos de isoxazolinas, composicion para el control de parasitos en base al compuesto, metodo de control de parasitos y uso del compuesto para tal fin | |
RU2011142978A (ru) | Противовирусные соединения и их применения | |
AR074790A1 (es) | Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente. | |
JP2016506960A5 (es) | ||
AR056882A1 (es) | Derivados del fungicida n- cicloalquil- bencil- amida | |
BRPI0607015A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
AR070582A1 (es) | Arilpirrolinas insecticidas y procedimiento para prepararlos | |
JP2013531029A5 (es) | ||
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
AR098673A1 (es) | Herbicidas de pirrolidinona | |
AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
RS53641B1 (en) | PYRAZOLOPYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | |
AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
RU2017134973A (ru) | Бутиролактоны в качестве гербицидов | |
AR089910A1 (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas | |
AR069368A1 (es) | Mezclas fungicidas | |
RS51430B (en) | Pyridine-pyrazine derivatives USED AS HERBICIDES | |
RU2014121205A (ru) | Производные азолов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |